ClinVar Miner

Submissions for variant NM_000419.5(ITGA2B):c.3091del (p.Leu1031fs)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen Platelet Disorders Variant Curation Expert Panel, ClinGen RCV002511541 SCV002820937 likely pathogenic Glanzmann thrombasthenia 2022-04-07 reviewed by expert panel curation The NM_000419.5(ITGA2B):c.3091del variant causes a frameshift and subsequent stop loss, Leu1031TrpfsTer97. This results in the addition of 90 amino acids to the ITGA2B protein, beyond the cytoplasmic domain (PM4). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). At least one patient (Patient GT10 in PMID:25373348) with this variant displayed mucocutaneous bleeding and impaired aggregation with all agonists except ristocetin, which is highly specific for Glanzmann thrombasthenia. Additionally, αIIbβ3 surface expression was severely reduced, as measured by flow cytometry (PP4_strong). GT10 of PMID: 25373348 is compound heterozygous for the paternal c.1210+105A>G (classified Likely Pathogenic by the PD-EP) and the maternal c.3091delC variants (PM3). In summary this variant meets criteria to be classified as Likely Pathogenic for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PP4_strong, PM2_supporting, PM3, PM4. (VCEP specifications version 2; date of approval 03/15/2022)

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.